advancing innovation to save lives

GHTC fact sheet looks at role of R&D in advancing universal health coverage

GHTC released a new fact sheet examining how R&D of new drugs, vaccines, diagnostics, and other tools is a critical driver of universal health coverage. The resource looks at out how new and improved technologies can help expand access to care in low-resource communities, fill urgent treatment and prevention gaps to improve quality of care, overcome barriers to care among vulnerable populations, and generate health care system cost savings.

GHTC unveils new report on global health innovation at USAID

GHTC unveiled a new report examing how the US Agency for International Development’s (USAID) investments in global health innovation are an essential enabler in accelerating partner countries along the journey to self-reliance. It explores challenges and opportunities the agency faces in advancing this work and provides actionable recommendations for the administration and Congress to maximize the agency's health research and development activities.

Member Spotlight: PATH

PATH, in partnership with Sinapi Biomedical, recently launched a new medical device to combat postpartum hemorrhage. Ellavi is the first commercially-available, low-cost, fully assembled uterine balloon tamponade.
Learn More

GHTC works to save and improve lives by encouraging the research and development of essential health technologies. We bring together more than 25 nonprofit organizations, academic institutions, and aligned businesses to advance policies to accelerate the creation of new drugs, vaccines, diagnostics, and other tools that bring healthy lives within reach for all people.

Why we're needed

Health technologies have the potential to save millions of lives. New tools are needed to slow the global threat of diseases, including HIV/AIDS, malaria, tuberculosis, and neglected tropical diseases, and tackle many other pressing health needs. For diseases and conditions primarily affecting people in the world’s poorest places, there is little to no commercial market to spur R&D. Strong investment and innovative solutions are needed to catalyze the development of new technologies to bring health and opportunity within reach for all people.

Learn more

Representatives Anna Eshoo and Mario Diaz-Balart and developers of the RTS,S malaria vaccine honored with GHTC Innovating for Impact Awards
GHTC yesterday honored Congresswoman Anna Eshoo (D-CA) and Congressman Mario Diaz-Balart (R-FL) for their leadership in supporting global health research and development (R&D) at its 2019 Innovating for Impact Awards, an initiative celebrating the US policymakers and partnerships driving global health innovation. GHTC also recognized the partnership that developed the RTS,S malaria vaccine—the world’s first malaria vaccine—for its efforts to advance this breakthrough technology.
Learn More

GHTC sends letter urging Congressional appropriators to include report language on BARDA in F20 bill

GHTC sent a letter to House and Senate appropriators urging them to include in the final fiscal year (FY) 2020 Labor, Health and Human Services, Education, and Related Agencies bill report language emphasizing the role of the Biomedical Advanced Research and Development Authority (BARDA) in advancing R&D for naturally-occurring health threats and requesting a delineation of BARDA’s investments in this area in its annual five-year budget plan. 

View All News & Events

Member Event

PATH/Doune Porter
ASTMH 68th Annual Meeting
American Society of Tropical Medicine & Hygiene
Learn More

Member Event

PATH/Georgina Goodwin
2019 Global Health Landscape Symposium
Global Health Council
Learn More
View All Events
PATH/Eric Becker
Research Roundup: First new HIV strain discovered in 19 years, Takeda vaccine for dengue, and researchers use drones to pilot a new tool to fight malaria

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

Read More
PATH/Satvir Malhotra
Research Roundup: New Zika blood test, TB vaccine shows sustained protection, first Lassa fever vaccine set for trial by year's end

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

Read More
View Breakthroughs Blog

Our members work to improve health worldwide